Evidence map›Paper›PMID 32725107›Full record

ArticleEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology2020

Predictors of recurrence of atrial fibrillation within the first 3 months after ablation.

Matthias Daniel Zink, Winnie Chua, Stef Zeemering, Luigi di Biase, Bayes de Luna Antoni, Callans David, Gerhard Hindricks, Karl Georg Haeusler, Hussein R Al-Khalidi, Jonathan P Piccini and 11 more

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02227550 (An Investigator-driven, Prospective, Parallel-group, Randomised, Open, Blinded Outcome Assessment), which is not on this map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02227550 phase4completednot on this map

An Investigator-driven, Prospective, Parallel-group, Randomised, Open, Blinded Outcome Assessment (PROBE), Multi-centre Trial to Determine the Optimal Anticoagulation Therapy for Patients Untergoing Catheter Ablation of Atrial Fibrillation

TypeinterventionalSponsorAtrial Fibrillation NetworkRan2014 to 2017Enrolled676ConditionsAtrial FibrillationArmsVitamin K antagonist, Apixaban
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. P-wave duration and atrial fibrillation recurrence after catheter ablation: a systematic review and meta-analysis.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2023
    Pooled it
  2. Identifying the prognostic significance of early arrhythmia recurrence during the blanking period and the optimal blanking period duration: insights from the DECAAF II study.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2023
    Trial
  3. Article
  4. Individualized dynamic ablation strategy for persistent atrial fibrillation based on ibutilide response.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. General anaesthesia compared to conscious sedation for first-time atrial fibrillation catheter ablation-a Danish nationwide cohort study.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2024
    Article
  12. Article
  13. Disturbed atrial metabolism, shear stress, and cardiac load contribute to atrial fibrillation after ablation: AXAFA biomolecule study.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2024
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 16 institutions in 9 countries.

Matthias Daniel ZinkDepartment of Internal Medicine I, University Hospital RWTH Aachen, Aachen, Germany.
Winnie ChuaInstitute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK.
Stef ZeemeringDepartment of Physiology, Cardiovascular Research Institute Maastricht (CARIM), Universiteitsingel 50, 6229 ER Maastricht, Netherlands.
Luigi di BiaseDepartment of Medicine (Cardiology), Albert Einstein College of Medicine at Montefiore Hospital, Montefiore-Einstein Center for Heart & Vascular Care New York, NY, USA.
Bayes de Luna AntoniAutonomous University of Barcelona and Institut Català Ciències Cardiovasculars (ICCC)-St. Pau Hospital, Barcelona, Spain.
Callans DavidCardiology Division, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Gerhard HindricksUniversity of Leipzig, Heart Center Leipzig, Leipzig, Germany.
Karl Georg HaeuslerDepartment of Neurology, University Hospital Würzburg, Würzburg, Germany.
Hussein R Al-KhalidiDepartment of Cardiac Electrophysiology, Duke University Medical Center, Duke Clinical Research Institute, Durham, NC, USA.
Jonathan P PicciniDepartment of Cardiac Electrophysiology, Duke University Medical Center, Duke Clinical Research Institute, Durham, NC, USA.
Lluís MontArrhythmia Section, Universitat de Barcelona, Hospital Clinic, Barcelona, Catalonia, Spain.
Jens Cosedis NielsenDepartment of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
Luis Alberto EscobarAutonomous University of Barcelona and Institut Català Ciències Cardiovasculars (ICCC)-St. Pau Hospital, Barcelona, Spain.
Joseph de BonoDepartment of Cardiology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
Isabelle C Van GelderDepartment of Cardiology and Thorax Surgery, UMCG Thorax Center, University of Groningen, Groningen, The Netherlands.
Tom de PotterDepartment of Cardiology, Electrophysiology section, Cardiovascular Center, OLV Hospital, Aalst, Belgium.
Daniel ScherrDepartment of Physiology, Cardiovascular Research Institute Maastricht (CARIM), Universiteitsingel 50, 6229 ER Maastricht, Netherlands.
Sakis ThemistoclakisUnit of Electrophysiology and Cardiac Pacing, Dell'Angelo Hospital, Mestre-Venice, Italy.
Derick ToddDepartment of EP, Devices and ICC, Liverpool Heart and Chest Hospital, Liverpool, UK.
Paulus KirchhofInstitute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK.
Ulrich SchottenDepartment of Physiology, Cardiovascular Research Institute Maastricht (CARIM), Universiteitsingel 50, 6229 ER Maastricht, Netherlands.
Maastricht University · NLClinical Research Institute · USUniversitat Autònoma de Barcelona · ESUniversity of Birmingham · GBAarhus University Hospital · DKAlbert Einstein College of Medicine · USHospital of the University of Pennsylvania · USLeipzig Heart Institute · DEMedical University of Graz · ATOnze Lieve Vrouwziekenhuis Hospital · BEOspedale dell' Angelo · ITUniversitat de Barcelona · ESUniversitätsklinikum Würzburg · DEUniversity Hospitals Birmingham NHS Foundation Trust · GBUniversity of Groningen · NLUniversity of Liverpool · GB

Funding

British Heart Foundation FS/13/43/30324Medical Research Council
6 · The paper itself

Abstract

aimsFreedom from atrial fibrillation (AF) at 1 year can be achieved in 50-70% of patients undergoing catheter ablation. Recurrent AF early after ablation most commonly terminates spontaneously without further interventional treatment but is associated with later recurrent AF. The aim of this investigation is to identify clinical and procedural factors associated with recurrence of AF early after ablation. METHODS AND

resultsWe retrospectively analysed data for recurrence of AF within the first 3 months after catheter ablation from the randomized controlled AXAFA-AFNET 5 trial, which demonstrated that continuous anticoagulation with apixaban is as safe and as effective compared to vitamin K antagonists in 678 patients undergoing first AF ablation. The primary outcome of first recurrent AF within 90 days was observed in 163 (28%) patients, in which 78 (48%) patients experienced an event within the first 14 days post-ablation. After multivariable adjustment, a history of stroke/transient ischaemic attack [hazard ratio (HR) 1.54, 95% confidence interval (CI) 0.93-2.6; P = 0.11], coronary artery disease (HR 1.85, 95% CI 1.20-2.86; P = 0.005), cardioversion during ablation (HR 1.78, 95% CI 1.26-2.49; P = 0.001), and an age:sex interaction for older women (HR 1.01, 95% CI 1.00-1.01; P = 0.04) were associated with recurrent AF. The P-wave duration at follow-up was significantly longer for patients with AF recurrence (129 ± 31 ms vs. 122 ± 22 ms in patients without AF, P = 0.03).

conclusionHalf of all early AF recurrences within the first 3 months post-ablation occurred within the first 14 days post-ablation. Vascular disease and cardioversion during the procedure are strong predictors of recurrent AF. P-wave duration at follow-up was longer in patients with recurrent AF.

trial registrationClinicaltrials.gov identifier NCT02227550.

Indexed as

Atrial FibrillationCatheter AblationAgedFemaleHumansRecurrenceRetrospective StudiesRisk FactorsTreatment OutcomeAblationApixabanAtrial fibrillationAXAFABlanking periodEarly recurrence

Identifiers

PMID32725107
PMCPMC7478316
OpenAlexW3045708564

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.